Prévalence de la dyslipidémie chez les patients atteints de diabète de type 2 à Bouaké, Côte d'Ivoire
Résumé
Texte intégral :
PDFRéférences
Wanvoegbe F, Agbodande K, Codjo L, Saizonou F, Alassani A, Sonou A et al. Dyslipidémie athérogène chez le diabétique de type 2 à Cotonou. Journal de la Société de Biologie Clinique du Bénin 2017 : 71-52. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022; 183: 109-193. Abou-Seif MA, Youssef AA. Evaluation of some biochemical changes in diabetic patients. Clinica Chimica Acta 2004; 346: 161-704. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. The Lancet 1997; 349: 1269-765. Shahwan MJ, Jairoun AA, Farajallah A, Shanabli S. Prevalence of dyslipidemia and factors affecting lipid profile in patients with type 2 diabetes. Diabetes & Metabolic Syndrome 2019; 13: 2387-926. Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia 2015; 58: 8867. Taskinen MR. Diabetic dyslipidemia. Atheroscler Suppl 2002; 3: 47-518. Gadi R, Samaha FF. Dyslipidemia in type 2 diabetes mellitus. Curr Diab Rep 2007; 7: 228-349. Khan SR, Ayub N, Nawab S, Shamsi TS. Triglyceride profile in dyslipidaemia of type 2 diabetes mellitus. J Coll Physicians Surg Pak 2008; 18: 270-310. Lokrou A. Hyperlipidémie et diabète en Côte d’Ivoire : étude transversale de 132 cas. Méd d’Afr Noire 1998 ; 45 : 555-711. WMA. The World Medical AssociationWMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects 202312. Diallo AM, Diallo MM, Baldé NM, Diakité M, Baldé TA, Bah A et al. Prévalence et association des différents critères du syndrome métabolique dans une population de diabétiques de type 2, en Guinée. Médecine Des Maladies Métaboliques 2012 ; 6 : 542-513. Kebede WM, Gizachew KD, Mulu GB. Prevalence and Risk Factors of Dyslipidemia among Type 2 Diabetes Patients at a Referral Hospital, North Eastern Ethiopia. Ethiop J Health Sci 2021; 31: 1267-7614. Benabadji N, Benzian Z, Amani MEA. Prise en charge de la dyslipidémie chez les patients diabétiques type 2 à l’EHU Oran. Ann Endocrinol 2016 ; 77 : 53315. Abdel-Aal NM, Ahmad AT, Froelicher ES, Batieha AM, Hamza MM, Ajlouni KM et al. Prevalence of dyslipidemia in patients with type 2 diabetes in Jordan. Saudi Med J 2008; 29: 1423-816. Mona HM, Sahar SA, Hend SM, Nanees AWA. Dyslipidemia in type 1 diabetes mellitus: Relation to diabetes duration, glycemic control, body habitus, dietary intake and other epidemiological risk factors. Egyptian Pediatric Association Gazette 2015; 63: 63-8
Stamouli M, Pouliakis A, Mourtzikou A, Skliris A, Panagiotou I, Mournianakis E et al. Evaluation of the lipid profile in type 2 diabetes mellitus patients in Greece. Clin Lab 2014; 60: 1593-60018. Pandya H, Lakhani JD, Dadhania J, Trivedi A. The Prevalence and Pattern of Dyslipidemia among Type 2 Diabetic Patients at Rural Based Hospital in Gujarat, India 2012; 12: 182-25719. Shehab A, Al-Rasadi K, Arafah M, AlHinai AT, Mahmeed WA, Bhagavathula AS et al. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving LipidLowering Drugs: A Sub-Analysis of the CEPHEUS Findings. Curr Vasc Pharmacol 2018; 16(4): 368-75
Renvois
- Il n'y a présentement aucun renvoi.